Top Markets
#1 DogBull DogBull +107.63%
#2 ADO Protocol ADO Protocol +51.91%
#3 Siacoin Siacoin +50.76%
#4 The Bitcoin Bull The Bitcoin Bull +44.24%
#5 MarsCoin MarsCoin +41.20%
#6 Ontology Gas Ontology Gas +23.42%
#7 Nockchain Nockchain +20.36%
#8 Apertum Apertum +20.22%
#9 UnifAI Network UnifAI Network +18.93%
#10 Falcon Finance Falcon Finance +16.52%
Coin of the day
DogBull DogBull
設定
言語
日本
通貨
USD
テーマ
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
株式のランク #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
株価
$0.63963115
最終同期: 2026-08-26
時価総額
$339.16M
変化（1日）
0.00%
変化（1年）
-35.23%
国
CN
取引 Jiangsu Recbio Technology Co., Ltd. (2179)

カテゴリー

Healthcare
Jiangsu Recbio Technology Co., Ltd.（2179）の株価履歴
終値の最高値: $0.64 （2026-08-01）

終値の最安値: $3.22 （2022-03-01）
Jiangsu Recbio Technology Co., Ltd. の株価履歴（2022 ～ 2026）
年間株価パフォーマンス
年 パフォーマンス
2026 (TTM) 4.07%
2025 -37.60%
2024 -16.16%
2023 -55.93%
2022 0.00%
類似企業または競合の株価
企業 株価 変化率 1年% 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.82 40.36%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.65%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.37 -11.93%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $147.48 512.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $748.60 4.92%
CH